In 1998, celecoxib was approved as the 1st selective COX-2 inhibitors.38 Celecoxib is a member of the coxib family, which included in the anatomical therapeutic chemical classification system; it is made of a 3-dimensional structure design of molecules with COX-2 selectivity.39 Celecoxib is a sulfonamide and can produce severe hypersensitivity reactions in patients with sulfonamide allergies, resulting in AEs that include asthma, nasal polyps, and rhinitis.40 This evidence concerns the gene PTGS2 and Nasal polyposis.